Cytosorbents (CTSO) Enterprise Value Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.23% |
| Dec 31, 2025 | 38.57% |
| Sep 30, 2025 | 38.83% |
| Jun 30, 2025 | 21.90% |
| Mar 31, 2025 | 13.06% |
| Dec 31, 2024 | -3.83% |
| Sep 30, 2024 | 16.46% |
| Jun 30, 2024 | 16.84% |
| Mar 31, 2024 | 15.21% |
| Dec 31, 2023 | 8.78% |
| Sep 30, 2023 | 19.54% |
| Jun 30, 2023 | 12.19% |
| Mar 31, 2023 | 2.02% |
| Dec 31, 2022 | -5.04% |
| Sep 30, 2022 | -7.93% |
| Jun 30, 2022 | -12.96% |
| Mar 31, 2022 | -67.74% |
| Dec 31, 2021 | -58.30% |
| Sep 30, 2021 | -57.12% |
| Jun 30, 2021 | -49.05% |
| Mar 31, 2021 | -62.58% |
| Dec 31, 2020 | -56.91% |
| Sep 30, 2020 | -64.13% |
| Jun 30, 2020 | -34.37% |
| Mar 31, 2020 | -20.43% |
| Dec 31, 2019 | -17.12% |
| Sep 30, 2019 | -15.48% |
| Jun 30, 2019 | -11.17% |
| Mar 31, 2019 | -11.97% |
| Dec 31, 2018 | -59.26% |
| Sep 30, 2018 | -60.35% |
| Jun 30, 2018 | -68.33% |
| Mar 31, 2018 | -72.89% |
| Dec 31, 2017 | -58.54% |
| Sep 30, 2017 | -49.52% |
| Jun 30, 2017 | -56.60% |
| Mar 31, 2017 | -12.44% |
| Dec 31, 2016 | -34.61% |
| Sep 30, 2016 | -22.66% |
| Jun 30, 2016 | -21.16% |
| Mar 31, 2016 | -19.86% |
| Dec 31, 2015 | -48.05% |
| Sep 30, 2015 | -57.66% |
| Jun 30, 2015 | -68.20% |